Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. Mai 2025 08:00 ET | Quelle: Remedy Plan Therapeutics

Remedy Plan Therapeutics Raises $18 Million Financing to Accelerate Advancement of Lead Asset RPT1G into Phase 1/2 Trials

Remedy Plan has raised an $18M insider round to advance their lead asset, RPT1G, into a Phase 1/2 clinical trial in patients with AML and high-risk MDS
18. Dezember 2024 08:30 ET | Quelle: Remedy Plan Therapeutics

Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor

Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor
03. November 2022 15:00 ET | Quelle: Roots Analysis

The NAMPT inhibitors market is projected to grow at an annualized rate of 15.08% during the period 2029-2040, claims Roots Analysis

London, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “NAMPT Inhibitors Market, 2022-2040” report to its list of offerings Cancer is one of the leading causes of...